Literature DB >> 9631245

Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.

P M Seldon1, P J Barnes, M A Giembycz.   

Abstract

Lipopolysaccharide (LPS)-induced liver injury in mice and LPS-induced tumor necrosis factor-alpha (TNF-alpha) generation by murine macrophages and hepatocytes are suppressed markedly by agents that elevate intracellular cAMP. Phosphodiesterase (PDE)-4 inhibitors, beta 2-adrenoceptor agonists, and E-series prostaglandins also attenuate the induction of the TNF-alpha gene in human monocytes in response to bacterial LPS. The mechanism of action of cAMP is unclear, but in the mouse, is believed to involve the generation of this anti-inflammatory cytokine, interleukin-10 (IL-10). In this article, we describe the results of studies designed to determine the extent to which IL-10 contributes to the suppression of TNF-alpha generation from LPS-stimulated human monocytes evoked by 8-bromo cyclic AMP (8-Br-cAMP), rolipram, salbutamol, and prostaglandin E2 (PGE2). LPS evoked a time- and concentration-dependent generation of TNF-alpha (t1/2 = 4.5 h; EC50 = 273 pg/mL), which was inhibited by exogenous human recombinant (h) IL-10 (IC50 = 124 pg/mL), and by rolipram (EC50 = 420 nM), 8-Br-cAMP (EC50 = 77 (microM), PGE2 (EC50 = 15 nM) and salbutamol (EC50 = 20 nM). In addition, 8-Br-cAMP, PGE2; and salbutamol (but not rolipram) augmented significantly LPS-induced IL-10 production (two-to-fivefold) under identical experimental conditions. Pretreatment of monocytes with an anti-IL-10 monoclonal antibody (MAb) that abolished the inhibitory action of a maximally effective concentration of exogenous hrIL-10, failed to attenuate the inhibitory effect of rolipram, PGE2, salbutamol, and 8-Br-cAMP. Anti-IL-10 was similarly inactive when the number of monocytes seeded was increased from 0.5 to 4 x 10(6)/mL or when measurements were made at 42 h post-LPS, a time when the concentration of IL-10 released was maximal. Collectively, these data suggest that in contrast to murine hepatocytes and macrophages, IL-10 does not mediate the inhibitory effect of cAMP-elevating drugs on TNF-alpha generation from human monocytes. Although the reason for this discrepancy is unclear, we suggest that the influence of cAMP on the transcriptional regulation of the TNF-alpha gene differs between species or when monocytes have differentiated into macrophages.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9631245     DOI: 10.1007/BF02737835

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  11 in total

1.  Differential inhibitory mechanism of cyclic AMP on TNF-alpha and IL-12 synthesis by macrophages exposed to microbial stimuli.

Authors:  D O Procópio; M M Teixeira; M M Camargo; L R Travassos; M A Ferguson; I C Almeida; R T Gazzinelli
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.

Authors:  Georg Schett; Victor S Sloan; Randall M Stevens; Peter Schafer
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

4.  Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10.

Authors:  P M Seldon; M A Giembycz
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

5.  The modulatory effects of prostaglandin-E on cytokine production by human peripheral blood mononuclear cells are independent of the prostaglandin subtype.

Authors:  Maaike M B W Dooper; Lianne Wassink; Laura M'Rabet; Yvo M F Graus
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

6.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

7.  Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipram.

Authors:  A C Soares; D G Souza; V Pinho; A T Vieira; M M Barsante; J R Nicoli; M Teixeira
Journal:  Br J Pharmacol       Date:  2003-11       Impact factor: 8.739

8.  Influence of phthalates on in vitro innate and adaptive immune responses.

Authors:  Juliana Frohnert Hansen; Claus Henrik Nielsen; Marianne Møller Brorson; Hanne Frederiksen; Marie-Louise Hartoft-Nielsen; Åse Krogh Rasmussen; Klaus Bendtzen; Ulla Feldt-Rasmussen
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

Review 9.  Translational Advances of Hydrofection by Hydrodynamic Injection.

Authors:  Luis Sendra; María José Herrero; Salvador F Aliño
Journal:  Genes (Basel)       Date:  2018-03-01       Impact factor: 4.096

10.  Efficacy of interleukin 10 gene hydrofection in pig liver vascular isolated 'in vivo' by surgical procedure with interest in liver transplantation.

Authors:  Luis Sendra; María José Herrero; Eva María Montalvá; Inmaculada Noguera; Francisco Orbis; Ana Díaz; Rafael Fernández-Delgado; Rafael López-Andújar; Salvador F Aliño
Journal:  PLoS One       Date:  2019-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.